For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 42,123 | 32,483* | 41,968 | - |
| General and administrative expense | 11,574 | 13,365* | 13,627 | - |
| Total operating expenses | 53,697 | 45,848 | 55,595 | - |
| Loss from operations | -53,697 | -45,848* | -55,595 | - |
| Interest income | 4,098 | 6,933* | 5,093 | - |
| Other expense, net | -62 | -119* | -108 | - |
| Net loss before income taxes | - | -39,034* | - | - |
| Effective tax rate | - | 0* | - | - |
| Net loss | -49,661 | -39,034* | -50,610 | -70,055 |
| Unrealized gain (loss) on investments | - | - | - | 102 |
| Comprehensive loss | - | - | - | -69,953 |
| Comprehensive loss attributable to noncontrolling interests | - | - | - | 0 |
| Net loss attributable to noncontrolling interests | - | 0* | 0 | - |
| Comprehensive loss attributable to cullinan | - | - | - | -69,953 |
| Net loss attributable to cullinan | - | -39,034 | -50,610 | - |
| Net loss | -45,485 | - | - | - |
| Basic EPS | -0.75 | -0.661 | -0.77 | - |
| Diluted EPS | -0.75 | -0.661 | -0.77 | - |
| Basic Average Shares | 60,462,000 | 59,025,000 | 59,075,000 | - |
| Diluted Average Shares | 60,462,000 | 59,025,000 | 59,075,000 | - |
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)